Urogen Pharma (NASDAQ:URGN – Get Free Report) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Urogen Pharma to announce earnings of $0.10 per share and revenue of $90.58 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 10:00 AM ET.
Urogen Pharma (NASDAQ:URGN – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million. On average, analysts expect Urogen Pharma to post ($0.20) EPS for the current fiscal year and $3.20 EPS for the next fiscal year.
Urogen Pharma Price Performance
Shares of Urogen Pharma stock opened at $33.75 on Thursday. The stock has a market capitalization of $1.65 billion, a P/E ratio of -17.05 and a beta of 1.57. The business has a 50 day simple moving average of $41.06 and a two-hundred day simple moving average of $31.15. Urogen Pharma has a 12 month low of $16.50 and a 12 month high of $50.81.
Insider Activity at Urogen Pharma
Wall Street Analyst Weigh In
Several analysts recently commented on the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $44.00 price target on shares of Urogen Pharma in a research report on Wednesday, July 15th. TD Cowen increased their price objective on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Thursday, October 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a $56.00 target price on shares of Urogen Pharma in a research note on Thursday, September 10th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Wednesday. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $52.38.
Read Our Latest Analysis on Urogen Pharma
About Urogen Pharma
UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.
UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.
The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.
See Also
- Five stocks we like better than Urogen Pharma
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
